相似文献
1
Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma.
Cancer Cell. 2013 Dec 9;24(6):777-90. doi: 10.1016/j.ccr.2013.11.003.
2
Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Epigenetics. 2015;10(6):460-6. doi: 10.1080/15592294.2015.1034416. Epub 2015 May 5.
3
Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Cell. 2013 Apr 11;153(2):320-34. doi: 10.1016/j.cell.2013.03.036.
4
Identification of super enhancer-associated key genes for prognosis of germinal center B-cell type diffuse large B-cell lymphoma by integrated analysis.
BMC Med Genomics. 2021 Mar 4;14(1):69. doi: 10.1186/s12920-021-00916-z.
5
Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma.
Haematologica. 2018 Dec;103(12):2049-2058. doi: 10.3324/haematol.2018.191684. Epub 2018 Aug 3.
6
Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors.
J Hematol Oncol. 2019 Jul 9;12(1):73. doi: 10.1186/s13045-019-0761-2.
7
Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Leukemia. 2017 Feb;31(2):479-490. doi: 10.1038/leu.2016.182. Epub 2016 Jun 24.
8
BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis.
Blood. 2023 Sep 28;142(13):1143-1155. doi: 10.1182/blood.2022019274.
9
Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
Clin Cancer Res. 2013 Nov 15;19(22):6183-92. doi: 10.1158/1078-0432.CCR-12-3904. Epub 2013 Sep 17.
10
BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
Mol Cell. 2015 Jun 18;58(6):1028-39. doi: 10.1016/j.molcel.2015.04.011. Epub 2015 May 14.
引用本文的文献
1
Cell Settling, Migration, and Stochastic Cancer Gene Expression Suggest Potassium Membrane Flux May Initiate pH Reversal.
Biomolecules. 2025 Aug 16;15(8):1177. doi: 10.3390/biom15081177.
2
Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications.
Front Pharmacol. 2025 Jun 18;16:1589455. doi: 10.3389/fphar.2025.1589455. eCollection 2025.
3
Super-enhancer-mediated circRNAs exhibit high splicing circularization diversity and transcriptional activity.
Nucleic Acids Res. 2025 Jun 6;53(11). doi: 10.1093/nar/gkaf505.
4
Enhancer profiling uncovers Jmjd1c as an essential suppressor in neuropathic pain by targeting Socs3.
Genes Dis. 2025 Jan 23;12(5):101545. doi: 10.1016/j.gendis.2025.101545. eCollection 2025 Sep.
5
Safely Targeting Cancer, the Wound That Never Heals, Utilizing CBP/Beta-Catenin Antagonists.
Cancers (Basel). 2025 Apr 29;17(9):1503. doi: 10.3390/cancers17091503.
6
Profiling triple-negative breast cancer-specific super-enhancers identifies high-risk mesenchymal development subtype and BETi-Targetable vulnerabilities.
Mol Cancer. 2025 May 13;24(1):141. doi: 10.1186/s12943-025-02342-6.
7
Updates on Toll-Like Receptor 10 Research.
Eur J Immunol. 2025 May;55(5):e202551840. doi: 10.1002/eji.202551840.
8
Super-enhancer profiling reveals ThPOK/ZBTB7B, a CD4+ cell lineage commitment factor, as a master regulator that restricts breast cancer cells to a luminal non-migratory phenotype.
Res Sq. 2025 Mar 31:rs.3.rs-6240646. doi: 10.21203/rs.3.rs-6240646/v1.
9
Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma.
ESMO Open. 2025 Apr 8;10(5):104499. doi: 10.1016/j.esmoop.2025.104499.
10
Studies on Gene Enhancer with KSHV mini-chromatin.
bioRxiv. 2025 Mar 24:2025.03.24.644916. doi: 10.1101/2025.03.24.644916.
本文引用的文献
1
SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.
Cancer Cell. 2013 Jun 10;23(6):826-38. doi: 10.1016/j.ccr.2013.05.002.
2
Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Cell. 2013 Apr 11;153(2):320-34. doi: 10.1016/j.cell.2013.03.036.
3
Transcriptional regulation and its misregulation in disease.
Cell. 2013 Mar 14;152(6):1237-51. doi: 10.1016/j.cell.2013.02.014.
4
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
Blood. 2013 May 16;121(20):4021-31; quiz 4250. doi: 10.1182/blood-2012-10-460063. Epub 2013 Feb 28.
5
Targeting MYCN in neuroblastoma by BET bromodomain inhibition.
Cancer Discov. 2013 Mar;3(3):308-23. doi: 10.1158/2159-8290.CD-12-0418. Epub 2013 Feb 21.
6
Genetic heterogeneity of diffuse large B-cell lymphoma.
Proc Natl Acad Sci U S A. 2013 Jan 22;110(4):1398-403. doi: 10.1073/pnas.1205299110. Epub 2013 Jan 4.
7
Bromodomain-containing protein 4 (BRD4) regulates RNA polymerase II serine 2 phosphorylation in human CD4+ T cells.
J Biol Chem. 2012 Dec 14;287(51):43137-55. doi: 10.1074/jbc.M112.413047. Epub 2012 Oct 19.
8
Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.
Cancer Cell. 2012 Oct 16;22(4):547-60. doi: 10.1016/j.ccr.2012.08.014.
9
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma.
Cancer Cell. 2012 Sep 11;22(3):359-72. doi: 10.1016/j.ccr.2012.07.014.
10
Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein.
J Biol Chem. 2012 Oct 19;287(43):36609-16. doi: 10.1074/jbc.M112.410746. Epub 2012 Sep 5.
Zotero 插件